PL318381A1 - Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition - Google Patents

Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition

Info

Publication number
PL318381A1
PL318381A1 PL95318381A PL31838195A PL318381A1 PL 318381 A1 PL318381 A1 PL 318381A1 PL 95318381 A PL95318381 A PL 95318381A PL 31838195 A PL31838195 A PL 31838195A PL 318381 A1 PL318381 A1 PL 318381A1
Authority
PL
Poland
Prior art keywords
arylothiopropanoloamine
adrenoreceptors
beta3
beta1
adrenoreceptor
Prior art date
Application number
PL95318381A
Other languages
English (en)
Inventor
Lee James Beeley
Mervyn Thompson
David Kenneth Dean
Nikesh Rasiklal Kotecha
John Michael Berge
Robert William Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415304A external-priority patent/GB9415304D0/en
Priority claimed from GB9423179A external-priority patent/GB9423179D0/en
Priority claimed from GBGB9510485.7A external-priority patent/GB9510485D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PL318381A1 publication Critical patent/PL318381A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/303—Cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3223—Esters of cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
PL95318381A 1994-07-29 1995-07-27 Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition PL318381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415304A GB9415304D0 (en) 1994-07-29 1994-07-29 Novel compounds
GB9423179A GB9423179D0 (en) 1994-11-17 1994-11-17 Novel compounds
GBGB9510485.7A GB9510485D0 (en) 1995-05-24 1995-05-24 Novel compounds

Publications (1)

Publication Number Publication Date
PL318381A1 true PL318381A1 (en) 1997-06-09

Family

ID=27267307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95318381A PL318381A1 (en) 1994-07-29 1995-07-27 Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition

Country Status (12)

Country Link
EP (1) EP0772585A1 (cs)
JP (1) JPH10503507A (cs)
CN (1) CN1159797A (cs)
AU (1) AU3254695A (cs)
BR (1) BR9508991A (cs)
CA (1) CA2196193A1 (cs)
CZ (1) CZ25597A3 (cs)
HU (1) HUT76800A (cs)
MX (1) MX9700765A (cs)
NO (1) NO970372L (cs)
PL (1) PL318381A1 (cs)
WO (1) WO1996004233A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605495D0 (en) * 1996-03-15 1996-05-15 Smithkline Beecham Plc Novel compounds
US5914339A (en) * 1996-05-14 1999-06-22 American Home Products Corporation Substituted 1,3-benzodioxoles
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
GB9703492D0 (en) * 1997-02-20 1997-04-09 Smithkline Beecham Plc Novel compounds
CO5011072A1 (es) * 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
CA2285213C (en) * 1998-01-30 2013-07-30 Boulder Scientific Company Silylated and n-silylated compound synthesis
US6495546B1 (en) 1998-04-06 2002-12-17 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
AUPP549998A0 (en) * 1998-08-26 1998-09-17 Fujisawa Pharmaceutical Co., Ltd. New compound
US7098248B2 (en) * 2001-07-09 2006-08-29 Research Development Foundation Beta-adrenergic blockade reversal of catabolism after severe burn
DE102008064003A1 (de) * 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
CN107266341B (zh) * 2017-06-23 2020-01-07 华东师范大学 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途
CN112442167A (zh) * 2019-08-28 2021-03-05 广东广山新材料股份有限公司 一种反应型阻燃剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
GB8801306D0 (en) * 1988-01-21 1988-02-17 Ici Plc Chemical compounds
GB9215844D0 (en) * 1992-07-25 1992-09-09 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
NO970372D0 (no) 1997-01-28
NO970372L (no) 1997-03-18
WO1996004233A1 (en) 1996-02-15
JPH10503507A (ja) 1998-03-31
CN1159797A (zh) 1997-09-17
AU3254695A (en) 1996-03-04
EP0772585A1 (en) 1997-05-14
BR9508991A (pt) 1997-10-21
CA2196193A1 (en) 1996-02-15
CZ25597A3 (cs) 1998-02-18
MX9700765A (es) 1997-05-31
HUT76800A (en) 1997-11-28

Similar Documents

Publication Publication Date Title
HUP0101275A3 (en) Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
HUP0001640A3 (en) N6 heterocyclic substituted adenosine derivatives, their use for production of pharmaceutical compositions and pharmaceutical compositions containing them
IL112558A (en) Neuroprotective pharmaceutical compositions of 4 phenylpinene derivatives and certain novel 4 phenylpinene compounds
HUP0004150A3 (en) Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
HUP0005001A2 (hu) EP4 receptor szelektív agonista hatású pirrolidinszármazékok és ezeket tartalmazó gyógyászati készítmények
SG47877A1 (en) Use of tetrahydrocarbazone derivatives as 5HT receptor agonists
HUP9901296A3 (en) Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
HUP0004225A3 (en) Pyridine derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL112249A0 (en) Heterocyclic pyrimidine derivatives and pharmaceutical compositions containing them
PL320358A1 (en) Novel derivatives of benzimidazole exhibiting anithistaminic properties
PL318381A1 (en) Derivatives of aryloxy- and arylothiopropanoloamine useful as agonists of beta3-adrenoreceptor and antagonists of beta1 and beta2 adrenoreceptors and their pharmaceutic composition
HUP0101688A3 (en) Heterocyclically substituted amides and their use for producing pharmaceutical compositions
PL331562A1 (en) Derivatives of tetraquinoline as antagonists of eaa
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
IL122705A0 (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
HUP0004142A3 (en) Carboxamide derivatives as 5-ht1f agonists and pharmaceutical compositions containing them
PL340282A1 (en) Novel derivatives of cyclopentene useful as antagonists of motilin receptor
HUT73670A (en) Use of indole derivatives as 5ht1 antagonists
PL335905A1 (en) Novel derivatives of pyridine and pharmaceutic compositions containing them
HUP0102025A3 (en) Derivatives of 1,3,4-oxadiazolone, pharmaceutical compositions containing them and their use
PL316757A1 (en) Benzamide derivatives and composition containing them as well as their application
PL321565A1 (en) Derivatives of 4-(1h0indol-1-yl)-1-substituted piepridine of antipsychotic properties